Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Clovis Oncology

    - PMLiVE

    Major prostate cancer screening trial launched in UK

    The £42m Transform trial will recruit men aged 50-74, with a lower age limit of 45 for some men

    - PMLiVE

    Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer

    Around 55,100 cases of prostate cancer are diagnosed in the UK every year

    - PMLiVE

    Novartis’ Pluvicto granted FDA approval for expanded prostate cancer use

    The authorisation approximately triples the number of patients eligible to receive the therapy

    - PMLiVE

    NICE recommends pharmaand’s Rubraca for advanced ovarian cancer

    An estimated 7,500 new cases of the disease were diagnosed in the UK between 2017 and 2019

    - PMLiVE

    ICR researchers uncover genes responsible for tumour progression in prostate cancer

    The findings could pave the way for new treatment approaches that improve patient outcomes

    - PMLiVE

    Prostate cancer blood test with ‘unprecedented accuracy’ cuts biopsies by 50%

    There is currently no national screening programme for prostate cancer in the UK

    - PMLiVE

    ICR study reveals how PARP inhibitor resistance develops in prostate cancer patients

    The research could pave the way for the development of new drugs that prevent drug resistance

    - PMLiVE

    AstraZeneca announces positive results for Truqap in phase 3 prostate cancer study

    More than 52,000 cases of prostate cancer are diagnosed in the UK every year

    - PMLiVE

    Pfizer shares positive phase 3 results for Talzenna combination in prostate cancer

    Up to 20% of patients will develop metastatic castration-resistant disease within five to seven years of diagnosis

    - PMLiVE

    J&J’s Erleada shows overall survival benefit in head-to-head prostate cancer study

    Approximately 300,000 new cases of the disease are diagnosed in the US every year

    - PMLiVE

    ICR researchers identify new drug target for advanced prostate cancer patients

    The team estimates that around 10% of patients have high levels of the BCL2 protein

    - PMLiVE

    Researchers develop immunotherapy to prevent prostate cancer treatment resistance

    The second-most common cancer in the UK affects more than 52,000 men every year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links